Kazuhiro Takahashi

ORCID: 0000-0003-1900-4389
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Radiopharmaceutical Chemistry and Applications
  • Medical Imaging Techniques and Applications
  • Systemic Lupus Erythematosus Research
  • Drug Transport and Resistance Mechanisms
  • Liver Diseases and Immunity
  • HIV/AIDS drug development and treatment
  • Diabetes and associated disorders
  • Alcohol Consumption and Health Effects
  • Diet, Metabolism, and Disease
  • Glioma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Pancreatitis Pathology and Treatment
  • MRI in cancer diagnosis
  • Ultrasound Imaging and Elastography
  • Advanced MRI Techniques and Applications
  • Glaucoma and retinal disorders
  • Cancer and Skin Lesions
  • Diabetes Treatment and Management
  • Corneal surgery and disorders
  • Viral gastroenteritis research and epidemiology

Saga University
2012-2025

Hamanomachi Hospital
2014-2025

Fukushima Medical University
2019-2025

National University Health System
2024

Chiang Mai University
2024

Teikyo University
2017-2022

Creative Commons
2022

University of Tsukuba
2022

Community Link
2022

American College of Surgeons
2022

Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a disease characterized by chronic, profound, disabling, and unexplained fatigue. Although it hypothesized that brain inflammation involved in the pathophysiology of CFS/ME, there no direct evidence neuroinflammation patients with CFS/ME. Activation microglia or astrocytes related to neuroinflammation. <sup>11</sup>C-(<i>R</i>)-(2-chlorophenyl)-<i>N</i>-methyl-<i>N</i>-(1-methylpropyl)-3-isoquinoline-carboxamide...

10.2967/jnumed.113.131045 article EN Journal of Nuclear Medicine 2014-03-24

The purpose of this study was to determine the safety, distribution, internal dosimetry, and initial human epidermal growth factor receptor 2 (HER2)–positive tumor images <sup>64</sup>Cu-DOTA-trastuzumab in humans. <b>Methods</b>: PET performed on 6 patients with primary or metastatic HER2-positive breast cancer at 1, 24, 48 h after injection approximately 130 MBq probe <sup>64</sup>Cu-DOTA-trastuzumab. Radioactivity data were collected from blood, urine, normal-tissue samples these...

10.2967/jnumed.112.118612 article EN Journal of Nuclear Medicine 2013-09-12

INTRODUCTION: Obesity is associated with cancer, including gastrointestinal (GI). Data from low (LICs) and lower-middle-income countries (MICs) are limited. METHODS: We utilized data the Global Burden of Disease Study 2019 to determine mortality GI cancer risk high body mass index (BMI) in these countries. RESULTS: Mortality rates cancers BMI increased LICs lower MICs, while burdens decreased or remained stable middle-income DISCUSSION: The cancer-related burden necessitating a concerted...

10.14309/ajg.0000000000002819 article EN The American Journal of Gastroenterology 2024-04-22

At is a promising radiohalogen for targeted α therapy. However, some astatinated compounds undergo deastatination in vivo, leading to unintended astatine accumulation nontarget tissues. Recently, group reported that the vivo stability of an astato on alkyl could be improved by placing specific substituents around group. We hypothesized such approach applied improve aromatic groups. designed and synthesized astatobenzene derivatives with neighboring different physical properties. In vitro...

10.1021/acs.jmedchem.4c02188 article EN Journal of Medicinal Chemistry 2025-01-05

Acoustic radiation force impulse (ARFI) is a new technology integrated into conventional B-mode ultrasonography. ARFI used to evaluate tissue stiffness in several organs, but this method has not been applied for liver fibrosis.The aim of study was determine whether elastography useful the evaluation fibrosis.This enrolled 55 consecutive patients with chronic disease who underwent biopsy histological assessment fibrosis by Metavir scoring system. Liver and 25 healthy volunteers evaluated...

10.1111/j.1478-3231.2009.02130.x article EN Liver International 2009-10-27

Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome, is associated with an increased risk developing lifestyle-related diseases including type 2 diabetes, cardiovascular and cerebral vessel disease. No current drug therapy provides the ideal effects decreasing inflammation while simultaneously improving fibrosis. Liraglutide glucagon-like peptide-1 receptor agonist that affects histological findings in patients non-alcoholic steatohepatitis (NASH). This...

10.1111/hepr.12351 article EN Hepatology Research 2014-05-05

Abstract Background and Aims The pathogenesis of non‐alcoholic fatty liver disease ( NAFLD ) is now focusing on its organ cross‐talk with not only adipose tissue but also systemic skeletal muscle. Cross‐sectional longitudinal studies were conducted to determine the role intramuscular content IMAC measured by computed tomography severity /non‐alcoholic steatohepatitis NASH ). Methods Two hundred eight J apanese patients / diagnosed biopsy enrolled into a cross‐sectional study. Twenty‐one in...

10.1111/jgh.12227 article EN Journal of Gastroenterology and Hepatology 2013-04-12

Summary Background With the development of direct‐acting anti‐virals ( DAA s), almost all patients with chronic hepatitis C virus HCV ) infection can achieve sustained viral response SVR ). Aim To evaluate short‐term risk HCC among by s, including those cirrhosis or previous . Methods This large‐scale, multicentre cohort study included 1,675 consecutive who achieved treatment interferon‐free sofosbuvir‐based regimens, divided into groups n = 152) without 1,523). The Kaplan‐Meier method and...

10.1111/apt.14380 article EN cc-by Alimentary Pharmacology & Therapeutics 2017-10-16

Background & AimsPatients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic (MASLD) face multifaceted burden which includes impaired health-related quality of life (HRQL) and potential stigmatization. We aimed to assess the in patients NAFLD relationship between experience stigma HRQL.MethodsMembers Global NASH Council created a survey about NAFLD. Participants completed 35-item questionnaire Liver Disease Burden (LDB) (7 domains), 36-item CLDQ-NASH (6...

10.1016/j.jhepr.2024.101066 article EN cc-by-nc-nd JHEP Reports 2024-03-12

Tenofovir alafenamide (TAF) has been newly approved for the treatment of chronic hepatitis B (CHB). We aimed to assess effectiveness and renal safety switching from entecavir (ETV) or nucleos(t)ide analogue (NA) combination therapy TAF.This multicentre, retrospective, cohort study included 313 consecutive CHB patients who switched TAF monotherapy after with ETV a over 2 years. Virological/laboratory responses were evaluated 48 weeks switchover. Chronic kidney disease (CKD) was defined as an...

10.1111/liv.14482 article EN Liver International 2020-04-18

Summary Background Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection. Aims To evaluate the longer term virological/biochemical effectiveness of TAF and renal safety sequential therapy in real‐world settings Methods This multi‐centre, retrospective cohort study included consecutive adult patients who were switched from NAs TAF. We assessed virological biochemical responses up 144 weeks....

10.1111/apt.17107 article EN Alimentary Pharmacology & Therapeutics 2022-06-23

A comparison between atezolizumab plus bevacizumab (ATEZO/BEVA) and lenvatinib (LEN) for the treatment of hepatocellular carcinoma (HCC) remains unclear.This study aimed to compare therapeutic effects safety ATEZO/BEVA LEN as first-line therapies HCC.This was a retrospective analysis 810 patients with HCC who underwent (n = 186) or 624) systemic therapy March 2018 2022 at 14 facilities. After propensity score matching, 304 (ATEZO/BEVA group: n 152; 152) were analyzed.After although there no...

10.1007/s11523-022-00921-x article EN cc-by-nc Targeted Oncology 2022-10-22

INTRODUCTION: The burden of alcohol-related complications is considerable, particularly alcohol-associated liver disease and alcohol use disorder (AUD). However, there are deficiencies in comprehensive epidemiological research focusing on these issues, especially among young women who display higher susceptibility to such compared with their male counterparts. We thus aimed determine the global conditions this vulnerable group. METHODS: Leveraging data from Global Burden Disease Study 2019,...

10.14309/ajg.0000000000002642 article EN The American Journal of Gastroenterology 2023-12-26

Abstract Tyrosine kinase 2 (TYK2), a member of the JAK family, has attracted attention as potential therapeutic target for autoimmune diseases. However, role TYK2 in CD8 + T cells and type 1 diabetes (T1D) is poorly understood. In this study, we generate Tyk2 gene knockout non-obese (NOD) mice demonstrate that loss inhibits development autoreactive T-BET cytotoxic lymphocytes (CTLs) by impairing IL-12 signaling resident dendritic cell-driven cross-priming CTLs pancreatic lymph node (PLN)....

10.1038/s41467-024-45573-9 article EN cc-by Nature Communications 2024-02-13

Abstract Background L-type amino acid transporter 1 (LAT1) is overexpressed in various cancers; therefore, radiohalogen-labeled derivatives targeting LAT1 have emerged as promising candidates for cancer radiotheranostics. However, 211 At-labeled exhibit instability against deastatination vivo, making it challenging to use At radiotherapy. In this study, with high dehalogenation stability were developed. Results We designed and synthesized new ([ At]At-NpGT, [ 125 I]I-NpGT, 18 F]F-NpGT) which...

10.1186/s41181-024-00244-4 article EN cc-by EJNMMI Radiopharmacy and Chemistry 2024-02-26

Abstract Purpose A probe for targeted alpha therapy (TAT) using the RGD peptide (Ga-DOTA-K([ 211 At]APBA)-c(RGDfK) ([ At] 1 )) with albumin-binding moiety (ABM) was recently developed. [ highly accumulated in tumors and significantly inhibited tumor growth U-87 MG tumor-bearing mice. However, high retention blood may cause critical adverse events, such as hematotoxicity. Therefore, we attempted to accelerate clearance of by competitively inhibiting binding albumin modulate pharmacokinetics...

10.1007/s00259-024-06695-w article EN cc-by European Journal of Nuclear Medicine and Molecular Imaging 2024-04-04

Background and Aims: Identifying patients with steatotic liver disease who are at a high risk of developing HCC remains challenging. We present deep learning (DL) model to predict development using hematoxylin eosin-stained whole-slide images biopsy-proven disease. Approach Results: included 639 did not develop for ≥7 years after biopsy (non-HCC class) 46 developed &lt;7 (HCC class). Paired cases the non-HCC classes matched by date institution were used training, remaining nonpaired...

10.1097/hep.0000000000000904 article EN cc-by-nc-nd Hepatology 2024-05-20

A whole-body positron emission tomograph called Headtome-IV has been developed, and its physical performance investigated. An in-plane spatial resolution of 4.5 mm was realized with stationary sampling at the center field view. The axial slice thicknesses were 9.5 9.0 for direct cross planes, respectively. By moving gantry framework axially, transaxial images 14 or 21 slices are obtained quasi-simultaneously. real-time large-scale cache memory system allowed corrections deadtime radionuclide...

10.1109/23.34594 article EN IEEE Transactions on Nuclear Science 1989-02-01

Abstract Background Spontaneous rupture is rare complication of hepatocellular carcinoma (HCC) with high mortality rate in cirrhotic cases. The aim this study was to determine the factors influencing prognosis cases spontaneously ruptured HCC and investigate outcomes treatments employed, especially transcatheter arterial embolization (TAE). Methods A retrospective multicenter conducted 48 patients spontaneous HCC. Conservative treatment employed 32 (ConT group) TAE performed 16 (TAE group)....

10.1186/1471-230x-9-29 article EN cc-by BMC Gastroenterology 2009-04-30
Coming Soon ...